TENX

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended January 31, 2002 (Form 10-Q).
Status: Development Stage Company. The firm is in the pre-clinical trial stage for its products and has no revenue-generating operations. It relies on debt and equity financing to fund research and development.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Increases: Research and Development (R&D) expenses for the nine months ended Jan 31, 2002, rose to $996,044 from $519,799 in the prior year. This was driven by a $421,000 increase in wages and contract salaries, plus higher costs for supplies and rent.
• Expense Decreases: General and Administrative (G&A) expenses for the nine months dropped to $623,499 from $915,486 in the prior year. This reduction is attributed to the absence of one-time professional service fees (legal, consulting, marketing, investor relations) incurred in 2001.
• Net Loss Expansion: Despite lower G&A expenses, the net loss for the nine months increased to $1,520,615 from $1,169,084. This was primarily due to a $157,036 decrease in "Other Income" (interest income) caused by falling interest rates and smaller invested cash balances.
• Cash Position: Cash and cash equivalents decreased from $4,250,898 (April 30, 2001) to $2,908,046 (January 31, 2002), reflecting a net cash outflow from operations of $1,497,526 over the nine-month period.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity Outlook: Management believes current cash reserves ($2.9 million) are sufficient to meet liquidity needs for the next 14 months. However, significant additional financing is required for future development and FDA-mandated clinical trials.
• Financing Strategy: The company is actively pursuing private/institutional financing and strategic alliances. There are no firm commitments for additional capital as of the filing date.
• Key Risks:
  • Failure to achieve results in pre-clinical studies or obtain FDA approval for clinical trials.
  • Inability to secure necessary funding, which could force delays, scaling back of programs, or sale of technology rights.
  • Patent enforcement risks and potential infringement of third-party patents.
  • Uncertainties in scaling manufacturing and obtaining market acceptance.
• Unusual Items/Equity Activity:
  • Issued warrants for 2,000,000 shares (exercise price $0.20) to a significant shareholder for investor services; vesting is contingent on a recapitalization approval.
  • Issued warrants for 5,500,000 shares (exercise prices $0.20 and $0.60) to a significant shareholder for investor services.
  • Issued 40,000 options to Directors for services rendered; no compensation expense was recorded under APB #25.

Investor Verification Checklist

• Cash Runway: Verify if the projected 14-month runway remains accurate given the high burn rate of ~$1.5M per nine months.
• Financing Commitments: Confirm if any strategic alliances or financing agreements have been secured since the filing date to fund Phase II trials.
• Regulatory Milestones: Monitor progress on pre-clinical studies and the timeline for FDA submission for Investigational New Drug (IND) applications.
• Dilution Risk: Assess the impact of outstanding warrants (7.5 million shares) and potential future equity issuances on existing shareholder ownership.
• Related Party Transactions: Review the terms of the notes payable and the valuation of warrants issued to significant shareholders for investor services.